EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY 4.0

No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study

Junki Ishii iD, Mitsuaki Nishikimi, Liesbet De Bus, Jan De Waele, Akihiro Takaba, Akira Kuriyama iD, Atsuko Kobayashi, Chie Tanaka, Hideki Hashi, Hideki Hashimoto, Hiroshi Nashiki, Mami Shibata und 17 weitere

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.00342-24 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Junki Ishii und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carbapenems, Critical Illness, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Whether empirical therapy with carbapenems positively affects the outcomes of critically ill patients with bacterial infections remains unclear. This study aimed to investigate whether the use of carbapenems as the initial antimicrobial administration reduces mortality and whether the duration of carbapenem use affects the detection of multidrug-resistant (MDR) pathogens. This was a post hoc analysis of data acquired from Japanese participating sites from a multicenter, prospective observational study [Determinants of Antimicrobial Use and De-escalation in Critical Care (DIANA study)]. A total of 268 adult patients with clinically suspected or confirmed bacterial infections from 31 Japanese intensive care units (ICUs) were analyzed. The patients were divided into two groups: patients who were administered carbapenems as initial antimicrobials (initial carbapenem group, n = 99) and those who were not administered carbapenems (initial non-carbapenem group, n = 169). The primary outcomes were mortality at day 28 and detection of MDR pathogens. Multivariate logistic regression analysis revealed that mortality at day 28 did not differ between the two groups [18 (18%) vs 27 (16%), respectively; odds ratio: 1.25 (95% confidence interval (CI): 0.59–2.65), P = 0.564]. The subdistribution hazard ratio for detecting MDR pathogens on day 28 per additional day of carbapenem use is 1.08 (95% CI: 1.05–1.13, P < 0.001 using the Fine-Gray model with death regarded as a competing event). In conclusion, in-hospital mortality was similar between the groups, and a longer duration of carbapenem use as the initial antimicrobial therapy resulted in a higher risk of detection of new MDR pathogens. IMPORTANCE We found no statistical difference in mortality with the empirical use of carbapenems as initial antimicrobial therapy among critically ill patients with bacterial infections. Our study revealed a lower proportion of inappropriate initial antimicrobial administrations than those reported in previous studies. This result suggests the importance of appropriate risk assessment for the involvement of multidrug-resistant (MDR) pathogens and the selection of suitable antibiotics based on risk. To the best of our knowledge, this study is the first to demonstrate that a longer duration of carbapenem use as initial therapy is associated with a higher risk of subsequent detection of MDR pathogens. This finding underscores the importance of efforts to minimize the duration of carbapenem use as initial antimicrobial therapy when it is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbapenemsCritical IllnessDrug Resistance, Multiple, BacterialAnti-Bacterial AgentsIntensive Care UnitsBacterial InfectionsHumansMaleProspective StudiesFemaleAgedMiddle AgedJapanAged, 80 and overBacteria

Stichwörter der Autor:innen

carbapenemcritically illinfectious diseaseinitial empirical therapyintensive care unitmultidrug resistance

Substanzen

CarbapenemsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
  • Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
  • JA Hiroshima General Hospital, Hiroshima, Japan.
  • Emergency and Critical Care Center, Kurashiki Central Hospital, Okayama, Japan.

ORCID-Profile: Junki Ishii, Akira Kuriyama

Zitieren

APA

Ishii, J., Nishikimi, M., De Bus, L., De Waele, J., Takaba, A., Kuriyama, A., Kobayashi, A., Tanaka, C., Hashi, H., Hashimoto, H., Nashiki, H., Shibata, M., Kanamoto, M., Inoue, M., Hashimoto, S., Katayama, S., Fujiwara, S., Kameda, S., Shindo, S., …, & DIANA study Japanese group (2024). No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00342-24

Vancouver

Ishii J, Nishikimi M, De Bus L, De Waele J, Takaba A, Kuriyama A, et al. No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00342-24

BibTeX
@article{Ishii2024,
  author = {Ishii, Junki and Nishikimi, Mitsuaki and De Bus, Liesbet and De Waele, Jan and Takaba, Akihiro and Kuriyama, Akira and Kobayashi, Atsuko and Tanaka, Chie and Hashi, Hideki and Hashimoto, Hideki and Nashiki, Hiroshi and Shibata, Mami and Kanamoto, Masafumi and Inoue, Masashi and Hashimoto, Satoru and Katayama, Shinshu and Fujiwara, Shinsuke and Kameda, Shinya and Shindo, Shunsuke and Komuro, Tetsuya and Kawagishi, Toshiomi and Kawano, Yasumasa and Fujita, Yoshihito and Kida, Yoshiko and Hara, Yuya and Yoshida, Hideki and Fujitani, Shigeki and Shime, Nobuaki and DIANA study Japanese group, DIANA study Japanese group},
  title = {No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.00342-24}
}
Kostenlos starten →